Showing 1331-1340 of 5603 results for "".
IgAN SOC: Strengths and Limits
https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Mechanism-Based Targeting: Why APRIL Matters in IgAN
https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.APRIL Uncovered: An Upstream Driver in IgAN
https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Personalizing First-Line Therapy for CLL
https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/Experts explore first-line therapy selection in CLL, including biomarker testing, time-limited vs continuous regimens, safety profiles, and recent trial data.From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
https://reachmd.com/programs/cme/real-world-igan-a-case-based-approach-to-maximizing-kidney-preservation/26635/Are you implementing the new KDIGO guidelines for IgA nephropathy? Learn how to apply them in clinical practice using a real-world patient case.From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/Explore how bispecific antibodies are moving earlier in the treatment paradigm of multiple myeloma, supported by pivotal data showing improved patient outcomes.Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.